These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20218016)

  • 1. Integrated equation to evaluate accumulation profiles of drugs eliminated by Michaelis-Menten kinetics.
    Lam G; Chiou WL
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):227-32. PubMed ID: 20218016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and simple method to predict dosage of drugs obeying simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics.
    Wagner JG
    Ther Drug Monit; 1985; 7(4):377-86. PubMed ID: 4082237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.
    McNamara PJ; Levy G; Gibaldi M
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):195-206. PubMed ID: 20218014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.
    Saganuwan SA
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):57. PubMed ID: 34635182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steady state population kinetics of intravenous phenytoin.
    Frame B; Beal SL
    Ther Drug Monit; 1998 Aug; 20(4):408-16. PubMed ID: 9712466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Michaelis-Menten elimination kinetics: areas under curves, steady-state concentrations, and clearances for compartment models with different types of input.
    Wagner JG; Szpunar GJ; Ferry JJ
    Biopharm Drug Dispos; 1985; 6(2):177-200. PubMed ID: 4005396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling.
    Jun H; Rong Y; Yih C; Ho J; Cheng W; Kiang TKL
    Drugs R D; 2020 Dec; 20(4):343-358. PubMed ID: 33026608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the difficulties of fitting the double Michaelis-Menten equation to kinetic data.
    Bates JH; Bates DA; Mackillop W
    J Theor Biol; 1987 Mar; 125(2):237-41. PubMed ID: 3657211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a programmable calculator to determine steady-state levels of drugs eliminated by parallel first-order and Michaelis-Menten kinetics.
    Crow JW; Levy G
    Am J Hosp Pharm; 1978 Sep; 35(9):1075-7. PubMed ID: 696752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-pass effect: nonlinear concept comprising an explicit solution of integrated Michaelis-Menten equation.
    Keller F; Scholle J
    J Pharm Sci; 1981 Feb; 70(2):195-8. PubMed ID: 7205226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance.
    Killilea T; Coleman R; Ludden T; Peck CC; Rose D
    Ther Drug Monit; 1989; 11(4):455-62. PubMed ID: 2741195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.
    Odani A; Hashimoto Y; Takayanagi K; Otsuki Y; Koue T; Takano M; Yasuhara M; Hattori H; Furusho K; Inui K
    Biol Pharm Bull; 1996 Mar; 19(3):444-8. PubMed ID: 8924916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury.
    Stowe CD; Lee KR; Storgion SA; Phelps SJ
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1452-61. PubMed ID: 11185666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model.
    Valodia PN; Seymour MA; McFadyen ML; Miller R; Folb PI
    Ther Drug Monit; 2000 Jun; 22(3):313-9. PubMed ID: 10850399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical approximations of sensitivities of steady state predictions to errors in parameter estimation: II. Michaelis-Menten kinetics.
    Gonda I
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):525-34. PubMed ID: 6520746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.
    Popović J
    Eur J Drug Metab Pharmacokinet; 2004; 29(3):205-14. PubMed ID: 15537173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1997 Aug; 20(4):346-51. PubMed ID: 9260732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.